Journal of Affective Disorders

Sunstone Therapies Celebrates Three Year Anniversary With More Than 100 Psychedelic-Assisted Therapy Treatments Completed

Retrieved on: 
Thursday, December 14, 2023
Veteran, Spectrum, Journal of Affective Disorders, Journal of Psychopharmacology, MAPS, Research, Psychopharmacology, Ketamine, JAMA Oncology, DSM-IV codes, Education, Palliative care, Cancer, University, Sunstone, Post-traumatic stress disorder, Patient, PAT, Journal, Johns Hopkins, Pharmaceutical industry

Rockville, Maryland, December 14, 2023 – Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development of clinical trials, announces it has completed more than 100 psychedelic-assisted therapy (PAT) treatments, involving eight different indications, in the three years since the company was founded.

Key Points: 
  • Rockville, Maryland, December 14, 2023 – Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development of clinical trials, announces it has completed more than 100 psychedelic-assisted therapy (PAT) treatments, involving eight different indications, in the three years since the company was founded.
  • Manish Agrawal MD, CEO and Co-founder of Sunstone Therapies, said: “The development of psychedelic-assisted therapy, and the understanding of the impact it can have, has progressed so much over the last three years.
  • We are using the extensive experience we have gained in delivering these therapies, through sponsored clinical trials and our own investigator-initiated studies, to develop a patient-centric delivery model that can be scaled responsibly in the real world.
  • Delivery of psychedelic therapies is complex, requiring significant capabilities and experience in logistics, infrastructure and training, as well as clinical care.

New Research Demonstrates Clinical Effectiveness of Digital Treatment at Improving Insomnia and Comorbid Mental and Physical Health Issues

Retrieved on: 
Monday, October 9, 2023
Page, Doctor of Philosophy, Anxiety, Cognitive behavioral therapy, Cerebrovascular disease, Sleep, Sleep medicine, Nation, Therapy, Psychology, Ageing, University, Dave's Picks Volume 38, Digital, Comorbidity, Disease, Cancer, Randomized controlled trial, Brain damage, Spectrum, Insomnia, Meta-analysis, DSM-IV codes, Journal of Affective Disorders, Research, Depression, SAN, Survivor, RCT, CBT, Nuffield Department of Population Health, ASCO, WSO, PMID, Disability, Systematic review, Canadian International Council, PMCID, Neurorehabilitation and Neural Repair, University of Oxford, Patient, Pharmaceutical industry, Nursing, Dietary supplement, Sleepio, Stroke

SAN FRANCISCO and OXFORD, England, Oct. 9, 2023 /PRNewswire-PRWeb/ -- Big Health, the leader in digital therapeutics for the most common mental health conditions, announced today the publication of two, peer-reviewed studies demonstrating the effects of its flagship digital insomnia treatment Sleepio in individuals with co-morbid insomnia and clinically significant anxiety as well as in stroke survivors. 

Key Points: 
  • Digital cognitive behavioral therapy (dCBT) has long been evidenced as an effective treatment for insomnia and anxiety — key findings from these studies provide new insights into Sleepio's impact.
  • In a separate study among stroke survivors, 71% achieved remission using Sleepio compared to 30% of control participants.
  • Individuals with insomnia are three times more likely to develop anxiety than healthy sleepers.
  • [1] Additionally, comorbid insomnia and anxiety are associated with greater severity of both conditions — as well as increased symptoms of depression and poorer physical health.

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)

Retrieved on: 
Wednesday, September 27, 2023
Emory University, Acute stress disorder, Spectrum, Obesity, Journal of Affective Disorders, Prevalence, Tuskegee Veterans Administration Medical Center, Intussusception (medical disorder), Nerve conduction study, Woman, Psychotherapy, Veteran, Research, Georgia Institute of Technology College of Computing, Attention, Appetite, ECOR, Biomarker, Plasma, Journal, Ghrelin, Publication, Kanimozhi NVN Somu, Atlanta, MD, Patient, United States Department of Veterans Affairs, ElectroCore, Disease, Behavioural sciences, Psychiatry, Post-traumatic stress disorder, Memory, PTSD, Medical device, Meat

The first paper entitled “Effect of transcutaneous cervical vagus nerve stimulation on declarative and working memory in patients with Posttraumatic Stress Disorder (PTSD): A pilot study” was authored by Tilendra Choudhary and the second, “Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial” was written by Kasra Moazzami.

Key Points: 
  • The first paper entitled “Effect of transcutaneous cervical vagus nerve stimulation on declarative and working memory in patients with Posttraumatic Stress Disorder (PTSD): A pilot study” was authored by Tilendra Choudhary and the second, “Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial” was written by Kasra Moazzami.
  • Both studies were conducted at Emory University and were published in the peer reviewed Journal of Affective Disorders.
  • PTSD is the third most common service-connected disorder in veterans and is associated with considerable morbidity and impairment in function.
  • The study of 15 symptomatic subjects with a clinical diagnosis of PTSD suggested that transcutaneous vagus nerve stimulation (tcVNS) improves attention, and declarative and working memory, in patients with PTSD as measured by multiple endpoints.

gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)

Retrieved on: 
Tuesday, July 25, 2023
Transfer, Working memory, American Psychiatric Association, Emory University, VNS, Spectrum, Frequency response, Hou, Accident, User experience, United States Department of Defense, DSM-IV codes, Radiology, Georgia Institute of Technology College of Computing, Research, Attention, Inflammation, ECOR, Journal, NVN, Georgia Tech, Autonomic nervous system, Manuscript, Trauma, ElectroCore, Psychiatry, Paper, Post-traumatic stress disorder, Memory, Journal of Affective Disorders, PTSD, Pharmaceutical industry, Medical device, Atlanta, Patient

PTSD is an extreme mental health condition associated with changes in multiple neurophysiological systems such as inflammation and the autonomic nervous system and contributing to deficits in memory.

Key Points: 
  • PTSD is an extreme mental health condition associated with changes in multiple neurophysiological systems such as inflammation and the autonomic nervous system and contributing to deficits in memory.
  • Many patients have limited or no response to currently available treatments for PTSD symptoms and associated cognitive dysfunction.
  • Vagus Nerve Stimulation (VNS) has been shown in preliminary studies to enhance function when paired with cognitive and motor tasks.
  • The study concluded the active group developed better attention and recall of paragraphs encoded with stimulation as well as for working memory tasks as compared to sham.

Osmind Announces Publication of Largest Real-World Study on Effectiveness of Ketamine Intravenous Therapy for Depression, Anxiety and Suicidal Ideation

Retrieved on: 
Tuesday, June 20, 2023
Mental Health, Health, Science, Pharmaceutical, Research, Insurance, Maintenance, Depression, Therapy, Suicide, Anxiety, MS, CDC, KIT, Anxiety disorder, Journal, DSM-IV codes, Patient, Medicine, Ketamine, RWE, Suicidal ideation, FDA, Mental health, McInnes, Journal of Affective Disorders, Pharmaceutical industry, Medical device, MD

The unique study, which is the largest of its kind, specifically found:

Key Points: 
  • The unique study, which is the largest of its kind, specifically found:
    KIT is effective for depression and anxiety.
  • KIT reduced symptoms by at least 50% after six infusions in ~50% of patients for depression and anxiety.
  • The concordance of outcomes between this study and Osmind’s previous study on acute ketamine outcomes ( McInnes et al.
  • Osmind collaborates with the research community to analyze anonymized, aggregated data to advance new diagnostics, therapeutics, and precision medicine approaches.

 Cybin to Participate at the 26th Annual Milken Institute Global Conference

Retrieved on: 
Friday, April 28, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Psychopharmacology, Systematic review, Inc., Depression, Journal of Affective Disorders, Event, Anxiety, Quality of life, PT, Bangladesh Technical Education Board, Mental, Milken Institute, DSM-IV codes, Patient, Journal of Psychopharmacology, Mental health, Safety, The Beverly Hilton, NYSE, Conference, World Health Organization, NEO, Nursing, Pharmaceutical industry

The Milken Institute is a nonprofit, nonpartisan think tank dedicated to connecting resources and innovation so the best ideas can succeed.

Key Points: 
  • The Milken Institute is a nonprofit, nonpartisan think tank dedicated to connecting resources and innovation so the best ideas can succeed.
  • To access the live panel discussion, please click here .
  • The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.
  • For more information on the Milken Institute and the upcoming conference visit www.milkeninstitute.org .

Mindbloom Announces Partnership with SHIFT To Offer Affordable At-Home Ketamine Therapy To Its Employees

Retrieved on: 
Tuesday, April 25, 2023
Consulting, Data Management, Alternative Medicine, Technology, Professional Services, Health, General Health, Mental Health, Other Technology, Human Resources, Telemedicine, Virtual Medicine, Survivor, Cleveland Clinic, Partnership, Depression, Houston Methodist Hospital, Anxiety, Workplace, NYU, Psychotherapy, Movement, Selective serotonin reuptake inhibitor, Journal, MAPS, UCSF, Cleveland, Trauma, Mental health, Journal of Affective Disorders, Pharmaceutical industry, Nursing

Mindbloom , the world’s largest provider of ketamine therapy, announced today a partnership with SHIFT , a tech-enabled management consulting firm, to provide at-home ketamine therapy as a benefit to its employees.

Key Points: 
  • Mindbloom , the world’s largest provider of ketamine therapy, announced today a partnership with SHIFT , a tech-enabled management consulting firm, to provide at-home ketamine therapy as a benefit to its employees.
  • Through this partnership, all SHIFT employees will have access to at-home ketamine therapy through Mindbloom for a fraction of the normal price.
  • “I am incredibly proud to partner with employers like SHIFT to increase access to transformative at-home ketamine therapy programs,” said Mindbloom Founder & CEO Dylan Beynon.
  • And in January, Mindbloom announced a partnership with This is Jane Project to offer affordable at-home ketamine therapy to trauma survivors.

Mindbloom partners with This is Jane Project to offer affordable at-home ketamine therapy to trauma survivors

Retrieved on: 
Monday, January 16, 2023
Cleveland Clinic, Education, Depression, The Plain Jane Project, Anxiety, Trauma, Partnership, Organization, MAPS, Woman, Cleveland, Journal, Journal of Affective Disorders, Houston Methodist Hospital, Selective serotonin reuptake inhibitor, Survivor, UCSF, Pleasure, NYU, Pharmaceutical industry, Medicine

Through this partnership, This is Jane Project’s members will be able to access Mindbloom’s at-home ketamine therapy programs at a substantial discount.

Key Points: 
  • Through this partnership, This is Jane Project’s members will be able to access Mindbloom’s at-home ketamine therapy programs at a substantial discount.
  • In addition to discounted treatment, Mindbloom is also providing education on ketamine therapy to members of the organization.
  • In December, Mindbloom announced a partnership with Kennedy Care, a leader in home care services across Michigan and Northern Ohio, to offer at-home ketamine therapy as an employee benefit.
  • "This is highly personal for me, and I’m incredibly proud that we’re partnering with This is Jane Project to increase access to the transformative and healing power of at-home ketamine therapy for survivors of trauma."

Mindbloom Announces Rollout of Ketamine Telehealth Employee Benefits Program with Kennedy Care, 15Five

Retrieved on: 
Wednesday, December 14, 2022
Cleveland Clinic, Depression, UCSF, Journal of Affective Disorders, Cleveland, Journal, MAPS, NYU, Selective serotonin reuptake inhibitor, Houston Methodist Hospital, Ageing, Partnership, Mental health, Anxiety, Pharmaceutical industry, Medicine

As of November, Kennedy Care employees can access at-home ketamine therapy through Mindbloom.

Key Points: 
  • As of November, Kennedy Care employees can access at-home ketamine therapy through Mindbloom.
  • In November, 15Five , a pioneer in HR talent management technology, became the first company to offer the benefit.
  • Mindbloom has offered ketamine therapy as a benefit for its own employees since launching in 2019.
  • Founded by three-time entrepreneur Dylan Beynon, Mindbloom aims to address the mental health crisis through at-home ketamine therapy.

Single Mom Beats the Odds and Helps Others, Too, with Ehalo Care

Retrieved on: 
Thursday, September 8, 2022
Nanotechnology, Solution, USDA, Parent, Anxiety, Skin, Journal, Depression, Absorption, Happiness, GMP, FDA, Mental health, Journal of Affective Disorders, Risk, Woman, Pharmaceutical industry, Amusement arcade, Grocery store, CBD

New CBD company focuses on strengthening relationships between moms and kids by promoting mental health

Key Points: 
  • Hsin Chen is a single mom who knows the mental challenges of raising children alone.
  • This was the basis of her new company, Ehalo Care.
  • Every Ehalo Care CBD product is formulated with pharmaceutical-grade ingredients and tested in a third-party lab to ensure THC Free and purity.
  • Ehalo Care offers premier CBD products specially formulated with moms in mind.